Sourcebio Share Discussion Threads

[base7] 16/12/2021 10:37

Exactly - & our share price has not yet reacted to what will be a very strong FY21 & a stronger than expected FY22 in prospect as the demand for testing is likely to surpass recent records, following a quieter November ( following the then change in Govt guidance)

[donmac101] 16/12/2021 09:31

Sourcebio on twitter
Say they are getting overwhelming demand for tests.

[rivaldo] 14/12/2021 12:58

New from Liberum, who say buy and have a 190p target:



"Liberum stays at 'buy' on SourceBio following emergence of Omicron

Analysts at Liberum reiterated their 'buy' recommendation and 190.0p target price on shares of SourceBio International, telling clients that there was room for the company to beat its estimates for 2022 following the appearance of Omicron.

PCR testing was now at its second-highest level since the pandemic began and the government had reintroduced Day 2 PCR testing for travellers returning to the UK, they pointed out.

There were also discussions to reintroduce mandatory Day 8 PCR testing for travellers.

All were positives for the provider of laboratory services.

Furthermore, it base business was trading at pre-pandemic levels, the analysts said.

All told, that left the company "well-positioned" to execute against their estimates for the 2021 financial year of £86.5m in sales and earnings before interest, taxes, depreciation and amortisation of £21.0m and to "potentially outperform in 2022."

"We have left estimates unchanged at this stage whilst the outlook for PCR testing volumes remains uncertain. We await an update in guidance from management in early 2022. Nevertheless, we believe there is upside potential to forecasts. We reiterate BUY and target price of 190p.

"[...] The 2022 testing outlook remains uncertain but if the demand for private PCR testing remains high and international travel continues, then Source is well-positioned to benefit and outperform on expectations."

[base7] 14/12/2021 07:42

SBI has been a poor investment ,for me , but recent Covid news must be boosting our revenues from PCR/LF testing substantially again , after a quieter Nov & we are likely to be ending the year strongly & starting the new year strongly too.
Perhaps The Market is overlooking the amount of revenue & cash flow generated by this division when C-19 is rife ?

[base7] 14/12/2021 07:40

SBI has been a poor investment ,for me , but recent Covid news must be boosting our revenues from PCR/LF testing substantially again , after a quieter Nov & we are likely to be ending the year strongly & starting the new year strongly too.
Perhaps The Market is overlooking the amount of revenue & cash flow generated by this division when C-19 is rife ?

[base7] 05/12/2021 08:22

PCR testing now needed before travel to the UK which should ensure a stronger 4th quarter than expected after the reduced testing was introduced in Oct-which should help our share price recover & move forward.

[9degrees] 28/11/2021 19:13

its an ill wind - this should reverse the previous news of reduced PCR testing in favour of LFT . PCR will take off as will SBI

[boonboon] 27/11/2021 17:39

Pcr tests now needed for day 2 tests. Should be good for Sourcebio.

[ptolemy] 22/11/2021 11:05

SBI recruiting....

[boonboon] 15/10/2021 11:40

https://www.google.com/amp/s/news.sky.com/story/amp/covid-19-testing-suspended-at-wolverhampton-laboratory-after-estimated-43-000-people-given-wrong-results-12434220I wonder if we'll pick up more tests as a result of this

[smithless] 14/10/2021 09:04

The options shouldn't stop them buying (look at Circassia another one of Mill's vehicles). I know Mills rates LeCoque, but his PLC experience from what I see via his interviews (Vox etc) is not very good. Being a CEO of a PLC is partly about managing expectations and how he let Liberium's ridicules forecasts remain in the market for so long is an example of this. At least Liberium's forecast are now behind the curve. Lets see if his M&A abilities are up to Mill's glowing expectations of him.

[masurenguy] 14/10/2021 08:25

Since the two principle directors have recently been awarded options over 3.35m shares they appear to have very little incentive to put their own cash on the line even at this virtually ATL shareprice.
No position.

[smithless] 14/10/2021 08:09

As bpc10 stated a while back, what a dog of a stock. Will hold onto what I have, but as the directors can't be bothered to buy at these levels (22% below the placing price) why should I!

[supernumerary] 28/9/2021 11:47

At least they have cash, and therefore choices. I see EKF did a super deal in this space today.

[vsb234] 28/9/2021 11:42

Government funded PCR testing will remain. Travel based PCR testing and pricing for any residual PCR testing for the travel industry is likley to reduce very quickly. There are many private providers chasing a reducing market and the travel industry wants to reduce the cost of testing as quickly as possible. Variants are a possibility and the siutation may change.

[jangaman] 28/9/2021 11:40

I think it's all about the cash at the moment and what they do with it...

[supernumerary] 28/9/2021 11:28

I'd be astonished if demand for PCR testing disappeared instantly. As long as covid cases remain high, there'll be a need for it, so I expect it to tail off gradually. Unless of course another 'interesting' variant appears...

[smithless] 28/9/2021 08:39

It would be nice if Jay LeCoque and other directors bought some stock at these discounted prices.

[smithless] 28/9/2021 07:53

So much for Liberums forecasts, which the market always thought were daft. I think my forecasts below are not that far out, so FY2021 eps of 36p (current p/e of 3.75x) and subject to what SBI does with the cash eps of 12p FY2022 (11x). Time will tell

[uncleoswald] 28/9/2021 07:41

Even though pre travel PCR testing demand may reduce in the UK, there must be huge demand for PCR testing in other countries, including the USA.

[brummy_git] 28/9/2021 07:23

Marvellous insights here from executive Chairman Jay LeCoque of Sourcebio after today's record H1 results.

Find out all the commentary here.

hxxps://www.voxmarkets.co.uk/articles/sourcebio-results-q-a-38e73be

[brummy_git] 28/9/2021 07:19

Shares in laboratory services & medical diagnostics firm SourcebioPlc look far too cheap.

Here's why.

www.linkedin.com/posts/paul-hill-a5994116_sbi-activity-6848500130241400833-_GHl